Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP694904.RArlwugGYF8vgr2fFELNvWUX9EDQlsHvcgD_l6ayFRQ5I130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP694904.RArlwugGYF8vgr2fFELNvWUX9EDQlsHvcgD_l6ayFRQ5I130_assertion type Assertion NP694904.RArlwugGYF8vgr2fFELNvWUX9EDQlsHvcgD_l6ayFRQ5I130_head.
- NP694904.RArlwugGYF8vgr2fFELNvWUX9EDQlsHvcgD_l6ayFRQ5I130_assertion description "[Four apolipoprotein (apo) E variants have been reported to be associated with lipoprotein glomerulopathy (LPG), which is characterized by type III hyperlipoproteinemia (type III HLP) and proteinuria and frequently leads to nephrotic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP694904.RArlwugGYF8vgr2fFELNvWUX9EDQlsHvcgD_l6ayFRQ5I130_provenance.
- NP694904.RArlwugGYF8vgr2fFELNvWUX9EDQlsHvcgD_l6ayFRQ5I130_assertion evidence source_evidence_literature NP694904.RArlwugGYF8vgr2fFELNvWUX9EDQlsHvcgD_l6ayFRQ5I130_provenance.
- NP694904.RArlwugGYF8vgr2fFELNvWUX9EDQlsHvcgD_l6ayFRQ5I130_assertion SIO_000772 11877595 NP694904.RArlwugGYF8vgr2fFELNvWUX9EDQlsHvcgD_l6ayFRQ5I130_provenance.
- NP694904.RArlwugGYF8vgr2fFELNvWUX9EDQlsHvcgD_l6ayFRQ5I130_assertion wasDerivedFrom befree-20150227 NP694904.RArlwugGYF8vgr2fFELNvWUX9EDQlsHvcgD_l6ayFRQ5I130_provenance.
- NP694904.RArlwugGYF8vgr2fFELNvWUX9EDQlsHvcgD_l6ayFRQ5I130_assertion wasGeneratedBy ECO_0000203 NP694904.RArlwugGYF8vgr2fFELNvWUX9EDQlsHvcgD_l6ayFRQ5I130_provenance.